ABSTRACT
Introduction and Aim Diabetes is a global health emergency with increasing prevalence and diabetes-associated morbidity and mortality. One of the challenges in optimising diabetes care is translating research advances in this heterogenous disease into clinical care. A potential solution is the introduction of precision medicine approaches into diabetes care.
We aim to develop a digital platform called ‘intelligent Diabetes’ (iDiabetes) to support a precision diabetes care model in Scotland and assess its impact on the primary composite outcome of all-cause mortality, hospitalisation rate, renal function decline and glycaemic control.
Methods and Analysis The impact of iDiabetes will be evaluated through a cluster-randomised controlled study, recruiting up to 22,500 patients with diabetes. Primary care general practices (GP) in the National Health Service Scotland Tayside Health Board are the units (clusters) of randomisation. Each primary care GP will form one cluster (approximately 400 patients per cluster), with up to 60 clusters recruited. Randomisation will be to iDiabetes (guideline support), iDiabetesPlus or usual diabetes care (control arm). Patients of participating primary care GPs are automatically enrolled to the study when they attend for their annual diabetes screening or are newly diagnosed with diabetes. A composite hierarchical primary outcome, evaluated using Win-Ratio statistical methodology, will consists of (I) all-cause mortality, (II) all-cause hospitalisation rate, (III) proportion with >40% eGFR reduction from baseline or new development of end-stage renal disease, (IV) proportion with absolute HbA1C reduction >0.5%. Outcomes will be evaluated after a 2-year median follow-up period. Comprehensive qualitative and health economic analyses will be conducted, assessing the cost-effectiveness, budget impact and user acceptability of the iDiabetes platform.
Ethics and Dissemination This study was reviewed by the NHS HRA and approved by East of Scotland Research Ethics Committee (reference:23/ES/0008). Study findings will be disseminated via publications, presented at scientific conferences and shared with patients and the public on the study website and social media.
Study registration ISRCTN18000901
Study Sponsor University of Dundee, no. 2-026-22. Contact: tascgovernance{at}dundee.ac.uk
Protocol version: V3.0, 22/09/2023
ARTICLE SUMMARY Strengths
iDiabetes is a novel precision medicine platform which is the first of its kind to evaluate a precision diabetes care model in a controlled trial
Real-world application in an existing healthcare system, with the entire regional diabetes population eligible for enrolment – results are therefore likely to be generalisable and the approach could be scaled up to a national level
The study analysis utilises a mixed-method approach allowing a comprehensive evaluation of all aspects of the precision medicine platform including impact on clinical outcomes, usability for both patients and clinicians, cost-effectiveness analysis, budget impact analysis and patient preferences.
Limitations
Study enrolment takes place when patients attend their routine clinical diabetes review - consequently a subpopulation of patients with limited healthcare access may be excluded
The patient-facing platform is only available in an English version and can only be accessed digitally, therefore patients with limited English or digital illiteracy may not benefit from the intervention to its full potential
Competing Interest Statement
YYL, DL, MA, RB, TC, JFD, PTD, AF, RH, SMcK, SM, MR, GT, HW and MW have no competing interests. ERP has received honoraria for speaking from Novo Nordisk, Lilly and Illumina. SB has received consultancy fees from Astra Zeneca, Bayer and GSK. SGC is a director and employee of MyWay Digital Health. CL has received consultancy fees from Amarin, Aztra Zeneca, Boehringher Ingelheim, Novartis and Vifor; and research grants from Applied Therapeutics, Anacardia, Astra Zeneca, British Heart Foundation, Boehringer Ingelheim, Chief Scientist Office, Eli Lilly, Horizon 2020 EU funding, JDRF, Moderna, NIHR-HTA, Roche Diagnostics, Novo Nordisk, Novartis, and UKRI. HCM has received honoraria from Novo Nordisk and Astra Zeneca. IRM has received honoraria from Astra Zeneca and Boehringer Ingelheim. DJW is a shareholder and cofounder of MyWay Digital Health.
Clinical Trial
ISRCTN18000901
Funding Statement
This work was funded by Chief Scientist Office, Scotland (grant number: PMAS-21-01).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The East of Scotland Research Ethics Committee (NHS Scotland) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Joint first author
Competing interests: YYL, DL, MA, RB, TC, JFD, PTD, AF, RH, SMcK, SM, MR, GT, HW and MW have no competing interests.
ERP has received honoraria for speaking from Novo Nordisk, Lilly and Illumina.
SB has received consultancy fees from Astra Zeneca, Bayer and GSK.
SGC is a director and employee of MyWay Digital Health.
CL has received consultancy fees from Amarin, Aztra Zeneca, Boehringher Ingelheim, Novartis and Vifor; and research grants from Applied Therapeutics, Anacardia, Astra Zeneca, British Heart Foundation, Boehringer Ingelheim, Chief Scientist Office, Eli Lilly, Horizon 2020 EU funding, JDRF, Moderna, NIHR-HTA, Roche Diagnostics, Novo Nordisk, Novartis, and UKRI.
HCM has received honoraria from Novo Nordisk and Astra Zeneca.
IRM has received honoraria from Astra Zeneca and Boehringer Ingelheim.
DJW is a shareholder and cofounder of MyWay Digital Health.
Manuscript title: to include study location Abstract 'Methods and Analysis': to include follow-up period Qualitative data collection and management: to clarify the content of the interviews, and the areas that the qualitative data will inform Quantitative data collection and management; Secondary outcomes: data and method used for assessing drug adherence clarified iDiabetes IQ engine performance testing: grammatical error NO CHANGE TO PREVIOUSLY SUBMITTED SUPPLEMENTAL FILES
Data Availability
Individual level patient data will not be made publicly available due to data privacy/GDPR regulations. Additional access to the final study dataset on Health Informatics Centre Trusted Research Environment (University of Dundee) will be approved by the chief investigator with an appropriate data sharing agreement in place.
